FRNM: Freenome, Inc.
Performance
FRNM -18.75%
Watchlist
Select an item
Summary
FRNM at a glance
FRNM returned -18.75% since Jul 21, 2026. Its worst drop since then was -40.50%, smaller than 37% of stocks on Redstone, and its Sharpe ratio of -0.59 beats 10% of stocks on Redstone. It hasn't paid a dividend since it listed.
Current Drawdown
-38.22%
Rolling Volatility
89.10%
Actions
Metrics
Risk Indicators*
Alpha-43.56%
Beta1.76x
Sharpe-0.59
Sortino-0.84
Omega0.90
Calmar-0.46
Martin-2.55
Profile
About FRNM
Freenome Inc is a development-stage, early cancer detection company developing blood-based screening tests leveraging a proprietary artificial intelligence/machine learning multiomics technology platform to transform multi-cancer and ultimately multi-disease detection.
- Sector
- Health Care
- Industry
- Services: Medical Laboratories
- Market cap
- $1.1B
- Listed
- Jul 2026
- Headquarters
- New York, NY
- Website
- freenome.com
Comparisons